lncRNA KTN1‑AS1 promotes glioma cell proliferation and invasion by negatively regulating miR‑505‑3p

Mu,Yulong; Tang,Qiang; Feng,Haiyan; Zhu,Luwen; Wang,Yan

doi:10.3892/or.2020.7821

lncRNA KTN1‑AS1 promotes glioma cell proliferation and invasion by negatively regulating miR‑505‑3p

Authors:
- Yulong Mu
- Qiang Tang
- Haiyan Feng
- Luwen Zhu
- Yan Wang
View Affiliations

Affiliations: Department of Surgery, Hanan Branch of The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150001, P.R. China, Rehabilitation Medicine Center of the Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150001, P.R. China, Shanghai Public Health Clinical Center, Jinshan, Shanghai 200001, P.R. China
Published online on: October 22, 2020 https://doi.org/10.3892/or.2020.7821
Pages: 2645-2655
Copyright: © Mu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma (GBM) is one of the most prevalent and aggressive central nervous tumors with high mobility and mortality. The prognosis of patients with GBM is poor. It is therefore essential to explore the therapeutic strategies for the treatment of GBM. Previous studies have demonstrated that the long non‑coding RNA (lncRNA) Kinectin 1‑Antisense RNA 1 (KTN1‑AS1) can participate in the development of several types of cancer. However, the underlying mechanism of KTN1‑AS1 in GBM remains unknown. The present study aimed to determine the potential role of KTN1‑AS1 in GBM. In this study, reverse transcription quantitative PCR analysis was conducted and the results demonstrated that KTN1‑AS1 was upregulated in GBM tissues and cell lines compared with normal tissues and astrocytes (NHA). Furthermore, KTN1‑AS1 knockdown decreased the viability and invasive ability of glioma cells in vitro and in vivo. In addition, high level of KTN1‑AS1 was correlated with poor prognosis in TCGA GBM database. Furthermore, microRNA‑505‑3p (miR‑505‑3p) was a promising target of KTN1‑AS1, and the suppressing effects of miR‑505‑3p on cell proliferation and invasive ability was reversed by downregulating KTN1‑AS1. Taken together, the results from the present provided novel insights into the roles of KTN1‑AS1 in GBM, and suggested that the KTN1‑AS1/miR‑505‑3p axis may be considered as a novel therapeutic target for the treatment of patients with GBM.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Le Rhun E, Preusser M, Roth P, Reardon DA, van den Bent M, Wen P, Reifenberger G and Weller M: Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 80:1018962019. View Article : Google Scholar : PubMed/NCBI
3	Bernstock JD, Mooney JH, Ilyas A, Chagoya G, Estevez-Ordonez D, Ibrahim A and Nakano I: Molecular and cellular intratumoral heterogeneity in primary glioblastoma: Clinical and translational implications. J Neurosurg. 23:1–9. 2019.
4	Aldape K, Zadeh G, Mansouri S, Reifenberger G and von Deimling A: Glioblastoma: Pathology, molecular mechanisms and markers. Acta Neuropathol. 129:829–848. 2015. View Article : Google Scholar : PubMed/NCBI
5	Delgado-Martín B and Medina MÁ: Advances in the knowledge of the molecular biology of glioblastoma and its impact in patient diagnosis, stratification, and treatment. Adv Sci. 7:19029712020. View Article : Google Scholar
6	Hara A, Kanayama T, Noguchi K, Niwa A, Miyai M, Kawaguchi M, Ishida K, Hatano Y, Niwa M and Tomita H: Treatment strategies based on histological targets against invasive and resistant glioblastoma. J Oncol. 2019:29647832019. View Article : Google Scholar : PubMed/NCBI
7	Garton ALA, Kinslow CJ, Rae AI, Mehta A, Pannullo SC, Magge RS, Ramakrishna R, McKhann GM, Sisti MB, Bruce JN, et al: Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas. J Neurosurg. 8:1–11. 2020. View Article : Google Scholar
8	Zhang X, Zhang W, Mao XG, Cao WD, Zhen HN and Hu SJ: Malignant intracranial high grade glioma and current treatment strategy. Curr Cancer Drug Targets. 19:101–108. 2019. View Article : Google Scholar : PubMed/NCBI
9	Li C, Jing H, Ma G and Liang P: Allicin induces apoptosis through activation of both intrinsic and extrinsic pathways in glioma cells. Mol Med Rep. 17:5976–5981. 2018.PubMed/NCBI
10	Tamura R, Tanaka T, Miyake K, Yoshida K and Sasaki H: Bevacizumab for malignant gliomas: Current indications, mechanisms of action and resistance, and markers of response. Brain Tumor Pathol. 34:62–77. 2017. View Article : Google Scholar : PubMed/NCBI
11	Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F and Ochiya T: Emerging roles of long non-coding RNA in cancer. Cancer Sci. 109:2093–2100. 2018. View Article : Google Scholar : PubMed/NCBI
12	Wei JW, Huang K, Yang C and Kang CS: Non-coding RNAs as regulators in epigenetics. Oncol Rep. 37:3–9. 2017. View Article : Google Scholar : PubMed/NCBI
13	Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, et al: The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression. Genome Res. 22:1775–1789. 2012. View Article : Google Scholar : PubMed/NCBI
14	Gaballa JM, Braga Neto MB, Ramos GP, Bamidele AO, Gonzalez MM, Sagstetter MR, Sarmento OF and Faubion WA Jr: The role of histone methyltransferases and long non-coding RNAs in the regulation of T cell fate decisions. Front Immunol. 9:29552018. View Article : Google Scholar : PubMed/NCBI
15	Spizzo R, Almeida MI, Colombatti A and Calin GA: Long non-coding RNAs and cancer: A new frontier of translational research. Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
16	Li CY, Zhang WW, Xiang JL, Wang XH, Wang JL and Li J: Integrated analysis highlights multiple long non-coding RNAs and their potential roles in the progression of human esophageal squamous cell carcinoma. Oncol Rep. 42:2583–2599. 2019.PubMed/NCBI
17	DeOcesano-Pereira C, Machado RAC, Chudzinski-Tavassi AM and Sogayar MC: Emerging roles and potential applications of non-coding RNAs in glioblastoma. Int J Mol Sci. 21:E26112020. View Article : Google Scholar : PubMed/NCBI
18	Connerty P, Lock RB and de Bock CE: Long non-coding RNAs: Major regulators of cell stress in cancer. Front Oncol. 10:2852020. View Article : Google Scholar : PubMed/NCBI
19	Renganathan A and Felley-Bosco E: Long noncoding RNAs in cancer and therapeutic potential. Adv Exp Med Biol. 1008:199–222. 2017. View Article : Google Scholar : PubMed/NCBI
20	Yang G, Lu X and Yuan L: lncRNA: A link between RNA and cancer. Biochim Biophys Acta. 1839:1097–1109. 2014. View Article : Google Scholar : PubMed/NCBI
21	Liu C, Li X, Hao Y, Wang F, Cheng Z, Geng H and Geng D: STAT1-induced upregulation of lncRNA KTN1-AS1 predicts poor prognosis and facilitate non-small cell lung cancer progression via miR-23b/DEPDC1 axis. Aging (Albany NY). 12:8680–8701. 2020. View Article : Google Scholar : PubMed/NCBI
22	Zhang L, Wang L, Wang Y, Chen T, Liu R, Yang W, Liu Q and Tu K: lncRNA KTN1-AS1 promotes tumor growth of hepatocellular carcinoma by targeting miR-23c/ERBB2IP axis. Biomed Pharmacother. 109:1140–1147. 2019. View Article : Google Scholar : PubMed/NCBI
23	Jiang Y, Wu K, Cao W, Xu Q, Wang X, Qin X, Wang X, Li Y, Zhang J and Chen W: Long noncoding RNA KTN1-AS1 promotes head and neck squamous cell carcinoma cell epithelial-mesenchymal transition by targeting miR-153-3p. Epigenomics. 12:487–505. 2020. View Article : Google Scholar : PubMed/NCBI
24	Cao W, Liu JN, Liu Z, Wang X, Han ZG, Ji T, Chen WT and Zou X: A three-lncRNA signature derived from the Atlas of ncRNA in cancer (TANRIC) database predicts the survival of patients with head and neck squamous cell carcinoma. Oral Oncol. 65:94–101. 2017. View Article : Google Scholar : PubMed/NCBI
25	General Assembly of the World Medical Association, . World medical association declaration of Helsinki: Ethical principles for medical research involving human subjects. J Am Coll Dent. 81:14–18. 2014.PubMed/NCBI
26	Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, et al: NCBI GEO: Archive for functional genomics data sets-update. Nucleic Acids Res. 41:D991–D995. 2013. View Article : Google Scholar : PubMed/NCBI
27	Kong B, Yang T, Chen L, Kuang YQ, Gu JW, Xia X, Cheng L and Zhang JH: Protein-protein interaction network analysis and gene set enrichment analysis in epilepsy patients with brain cancer. J Clin Neurosci. 21:316–319. 2014. View Article : Google Scholar : PubMed/NCBI
28	Hawkins SF and Guest PC: Multiplex analyses using real-time quantitative PCR. Methods Mol Biol. 1546:125–133. 2017. View Article : Google Scholar : PubMed/NCBI
29	Chen X, Robinson DG and Storey JD: The functional false discovery rate with applications to genomics. Biostatistics. 28:kxz0102019. View Article : Google Scholar
30	Zhang JF, Wang P, Yan YJ, Li Y, Guan MW, Yu JJ and Wang XD: IL-33 enhances glioma cell migration and invasion by upregulation of MMP2 and MMP9 via the ST2-NF-κB pathway. Oncol Rep. 38:2033–2042. 2017. View Article : Google Scholar : PubMed/NCBI
31	Yao Z, Zhang Y, Xu D, Zhou X, Peng P, Pan Z, Xiao N, Yao J and Li Z: Research progress on long non-coding RNA and radiotherapy. Med Sci Monit. 25:5757–5770. 2019. View Article : Google Scholar : PubMed/NCBI
32	Jalali S, Bhartiya D, Lalwani MK, Sivasubbu S and Scaria V: Systematic transcriptome wide analysis of lncRNA-miRNA interactions. PLoS One. 8:e538232013. View Article : Google Scholar : PubMed/NCBI
33	Gutschner T, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al: The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 73:1180–1189. 2013. View Article : Google Scholar : PubMed/NCBI
34	Li Y, Wang K, Wei Y, Yao Q, Zhang Q, Qu H and Zhu G: lncRNA-MIAT regulates cell biological behaviors in gastric cancer through a mechanism involving the miR-29a-3p/HDAC4 axis. Oncol Rep. 6:3465–3472. 2017.
35	Li C, Zheng H, Hou W, Bao H, Xiong J, Che W, Gu Y, Sun H and Liang P: Long non-coding RNA linc00645 promotes TGF-β-induced epithelial-mesenchymal transition by regulating miR-205-3p-ZEB1 axis in glioma. Cell Death Dis. 10:7172019. View Article : Google Scholar : PubMed/NCBI
36	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
37	Wu M, Wang G, Tian W, Deng Y and Xu Y: miRNA-based therapeutics for lung cancer. Curr Pharm Des. 23:5989–5996. 2018. View Article : Google Scholar : PubMed/NCBI
38	Shin VY and Chu KM: miRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol. 20:10432–10439. 2014. View Article : Google Scholar : PubMed/NCBI
39	Fridrichova I and Zmetakova I: MicroRNAs contribute to breast cancer invasiveness. Cells. 8:13612019. View Article : Google Scholar
40	Deng JH, Deng Q, Kuo CH, Delaney SW and Ying SY: miRNA targets of prostate cancer. Methods Mol Biol. 936:357–369. 2013. View Article : Google Scholar : PubMed/NCBI
41	Wang J, Liu H and Li M: Downregulation of miR-505 promotes cell proliferation, migration and invasion, and predicts poor prognosis in breast cancer. Oncol Lett. 18:247–254. 2019.PubMed/NCBI
42	Shi H, Yang H, Xu S, Zhao Y and Liu J: miR-505 functions as a tumor suppressor in glioma by targeting insulin like growth factor 1 receptor expression. Int J Clin Exp Pathol. 11:4405–4413. 2018.PubMed/NCBI